Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.

medRxiv : the preprint server for health sciences·2026
Same author

Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Jun 16, 2026

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

Off-label medication use in frontotemporal dementia.

Bei Hu1, Leslie Ross, John Neuhaus

  • 1Memory and Aging Center, Department of Neurology, University of California-San Francisco, San Francisco, CA 94143, USA.

American Journal of Alzheimer'S Disease and Other Dementias
|February 4, 2010
PubMed
Summary

Frontotemporal dementia (FTD) lacks FDA-approved treatments. This study found common use of Alzheimer's medications like acetylcholinesterase inhibitors (AChIs) and memantine in behavioral variant FTD (bvFTD), despite limited efficacy evidence.

Related Experiment Videos

Last Updated: Jun 16, 2026

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder.
  • Behavioral variant FTD (bvFTD) is the most common subtype of FTD.
  • Currently, no medications are FDA-approved for treating FTD.

Purpose of the Study:

  • To identify the most frequently prescribed medications for behavioral variant FTD (bvFTD).
  • To compare medication use in bvFTD with Alzheimer's disease (AD).

Main Methods:

  • Analysis of medication and demographic data from specialized dementia clinics.
  • Comparison of drug usage patterns between bvFTD and AD patient cohorts.
  • Logistic regression to assess the impact of demographic variables on medication use.

Main Results:

  • Acetylcholinesterase inhibitor (AChI) use was less frequent in bvFTD compared to AD after controlling for demographics.
  • Memantine use was similar between bvFTD and AD groups.
  • Overall use of FDA-approved AD or psychiatric medications was comparable between bvFTD and AD.

Conclusions:

  • Acetylcholinesterase inhibitors (AChIs) and memantine are commonly used in bvFTD despite a lack of proven efficacy.
  • Further clinical trials are necessary to establish effective treatments for bvFTD.
  • Evidence-based therapeutic strategies are needed for managing bvFTD symptoms.